1-3 of 3
Lekha Mikkilineni
Close
Sort by
Journal Articles

Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30 + lymphomas: results of a phase 1 trial

Clinical Trials & Observations
Jennifer N. Brudno, Danielle A. Natrakul, Jeremiah Karrs, Nisha Patel, Roberto Maass-Moreno, Mark A. Ahlman, Lekha Mikkilineni, Jennifer Mann, David F. Stroncek, Steven L. Highfill, Genevieve C. Fromm, Rashmika Patel, Stefania Pittaluga, James N. Kochenderfer
Journal: Blood Advances
Blood Adv (2024) 8 (3): 802–814.
https://doi.org/10.1182/bloodadvances.2023011470
Published: 2024
Includes: Supplemental data
Journal Articles

The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes

Clinical Trials & Observations
Aiman J. Faruqi, John A. Ligon, Paul Borgman, Seth M. Steinberg, Toni Foley, Lauren Little, Crystal L. Mackall, Daniel W. Lee, Terry J. Fry, Haneen Shalabi, Jennifer Brudno, Bonnie Yates, Lekha Mikkilineni, James Kochenderfer, Nirali N. Shah
Journal: Blood Advances
Blood Adv (2022) 6 (23): 6040–6050.
https://doi.org/10.1182/bloodadvances.2022007676
Published: 2022
Includes: Supplemental data
Journal Articles

Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days

Clinical Trials & Observations
Lekha Mikkilineni, Bonnie Yates, Seth M. Steinberg, Shilpa A. Shahani, John C. Molina, Tara Palmore, Daniel W. Lee, Rosandra N. Kaplan, Crystal L. Mackall, Terry J. Fry, Juan Gea-Banacloche, Theresa Jerussi, Veronique Nussenblatt, James N. Kochenderfer, Nirali N. Shah
Journal: Blood Advances
Blood Adv (2021) 5 (23): 5312–5322.
https://doi.org/10.1182/bloodadvances.2021004896
Published: 2021
Includes: Supplemental data